Novavax Inc

This advisory proposal asks shareholders to approve, on a non-binding basis, the compensation program for the company’s Named Executive Officers as disclosed in the proxy statement. Management seeks this annual endorsement to validate its pay philosophy — which emphasizes market-competitive base salaries, at-risk incentive cash bonuses tied to corporate and individual objectives, and equity awards (mix of time-vesting stock options and RSUs) to align long-term interests with stockholders — and to signal responsiveness to investors. The Board and Compensation Committee present this as affirming their compensation design that targets the 50th percentile of peers, uses an independent consultant (Pearl Meyer), and includes governance safeguards such as clawback and anti-hedging policies. The company notes prior stockholder outreach and that 72.3% supported the 2025 say-on-pay; management states it will consider the advisory vote outcome in future decisions. A FOR vote does not bind the Company but serves as important feedback; a negative result would typically trigger increased engagement and potential program design changes. Key contextual factors include Novavax’s strategic shift toward partnerships and R&D, 2025 operational milestones (including Sanofi milestone achievements and cost reductions), substantial equity grants to retain talent during transformation, and ongoing executive employment and severance arrangements that include change-in-control protections. For investors evaluating the merits, the vote reflects whether pay outcomes and disclosures sufficiently tie pay to performance and long-term value creation; central considerations are the composition and size of equity awards, disclosed incentive metrics (the 2025 Objectives), and governance features intended to mitigate excess risk. Given management’s stated rationale and the company’s prior outreach, the Board recommends FOR and will use the results to inform compensation governance moving forward.

This proposal requests shareholder approval to increase the reserve under Novavax’s principal equity compensation plan by 9.4 million shares to enable continued grants of options, RSUs and other equity awards. Management’s rationale is operational: equity is central to retention and hiring in a competitive biotech market and remains the principal long‑term incentive vehicle aligning executives, employees, and directors with stockholder outcomes. The Board considered historical burn rates, the company’s transformation from a COVID‑commercial company toward partnerships and R&D, and advice from the Compensation Committee’s independent consultant in determining the size of the increase. If approved, the additional shares would restore the plan’s capacity (management projects enough shares for roughly two years of awards at recent grant rates) and permit continued use of time‑based options and RSUs that the company favors for retention and alignment. Governance features described by management — including independent committee administration, limits on non‑employee director compensation, no repricing without shareholder approval, minimum vesting, and clawback provisions — are intended to reduce dilution risk and align the plan with institutional investor and proxy‑advisor norms. Key considerations for sophisticated investors include the incremental dilutive impact (projected increase in potential dilution to ~13.4% on a fully diluted basis if approved), how the share request compares to peer practices and burn rates, the mix and size of historical grants (notably large option and RSU awards to executives in 2025), and whether vesting and performance conditions adequately tie awards to long‑term value creation. Opponents might argue the request is large relative to current outstanding float and that management should optimize reuse of unvested awards or pursue cash alternatives; supporters will emphasize the company’s need to secure talent while pursuing partnerships and product development. The Board recommends FOR based on its view that the benefits of preserving an effective equity program outweigh the dilution, subject to the plan’s governance safeguards.

This proposal asks shareholders to expand the company’s employee stock purchase plan by one million shares and to set a defined cap mechanism (the reserve will be the lesser of 3,375,888 shares increased annually by 5% or 4,820,564 shares). Management frames the change as necessary because the existing ESPP run‑rate and historical participation suggest the current share pool would be exhausted well before the plan’s 2034 expiration. The ESPP is a broad‑based program (hundreds of employees eligible) designed to promote employee ownership and retention through discounted purchases (85% of market on the applicable lookback). From a governance perspective, the Amended ESPP retains limits required by Section 423 (per‑participant and annual dollar limits) and includes administrative flexibility to comply with local laws for non‑U.S. participants. For investors evaluating the proposal, the tradeoff is modest incremental dilution versus the retention, morale and recruiting benefits of a broadly accessible, discounted equity vehicle: quantitative dilution is limited (ESPP typically accounts for a small share of overall grants), while the program supports alignment across the employee base. Opposing views would focus on dilution and question whether cheaper non‑dilutive incentives or reallocating existing equity reserves would be preferable; proponents will note the program’s role in maintaining employee engagement and long‑term ownership trends. The Board recommends FOR as consistent with maintaining a competitive total rewards program while placing a hard cap on the plan’s growth.

This is a standard catch‑all proposal included in the notice to permit the transaction of any other business properly presented at the Annual Meeting or any adjournments. It does not propose a specific corporate action but preserves shareholder and management flexibility to address unexpected or ancillary matters that may arise before or at the meeting. From an analytical perspective, such items are typically either procedural (e.g., adjournments) or ministerial and rarely result in substantive contested votes; any substantive additional items would be accompanied by supplemental disclosure if required. Voting on this item is generally handled at the discretion of the proxies named on the form if no specific instructions are provided; brokers typically do not have discretionary voting power on non‑routine matters. Investors should expect that management and the Board will exercise their proxy discretion consistent with corporate governance practices and the best interests of shareholders; any material additional business brought before the meeting would be described in subsequent filings or meeting materials. Given its open‑ended nature, its practical impact is to ensure the meeting can address unforeseen but proper matters without needing to reconvene; shareholders concerned about surprise proposals should monitor the meeting agenda and any supplemental filings in advance.